Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

Changsong Qi, Jifang Gong, Jian Li, +23

Nature Medicine

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Yingying Xu, Yakun Wang, Jifang Gong, +20

Gastric Cancer

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

Changsong Qi, Chang Liu, Jifang Gong, +21

Nature Medicine

Cancer ImmunosurveillanceGastrointestinal OncologyMedicineGastrointestinal CancersImmunology +6

Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features

Yakun Wang, Li Sun, Zhongwu Li, +13

Gastric Cancer

Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial

Yakun Wang, Jifang Gong, Airong Wang, +15

EClinicalMedicine

Higher prevalence of human herpesvirus 8 DNA sequence and specific IgG antibodies in patients with pemphigus in China

Guanqing Wang, Hong‐Hui Xu, Yakun Wang, +5

Journal of the American Academy of Dermatology

Diagnostic VirologySpecific Igg AntibodiesHigher PrevalenceViral DiagnosticsVirus Epidemiology +7

YARS as an oncogenic protein that promotes gastric cancer progression through activating PI3K-Akt signaling

Cheng Zhang, Xiaoting Lin, Qian Zhao, +7

Journal of Cancer Research and Clinical Oncology

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial

Xiaotian Zhang, Liang Han, Ziyu Li, +41

The Lancet Oncology

D2 GastrectomySurgical OncologyEsophageal CancerGastrointestinal OncologyMedicine +8

First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.

Yakun Wang, Jifang Gong, Rongbo Lin, +17

Journal of Clinical Oncology

PathologyImmunotherapeuticsTumor BiologyGastrointestinal OncologyMetronomic Therapy +17

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers

Yakun Wang, Tianshu Liu, Gongyan Chen, +21

The Oncologist